Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tina Lin

Showing results (41-50 of 117) with videos related to

Pageof 12
Sort By:
The Journal of Clinical and Aesthetic Dermatology|December 28, 2018
Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% CreamNeal D Bhatia, David M Pariser, Leon Kircik, et al.
Journal of Drugs in Dermatology : JDD|July 14, 2018
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of TherapyDavid M Pariser, Lawrence J Green, Linda Stein Gold, et al.
Small (Weinheim an Der Bergstrasse, Germany)|June 27, 2017
Creation of Faceted Polyhedral Microgels from Compressed EmulsionsJing Fan, Shin-Hyun Kim, Zi Chen, et al.
The Journal of Dermatological Treatment|September 17, 2019
Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technologyEmil A Tanghetti, Linda Stein Gold, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque PsoriasisLeon H. Kircik, Kim A. Papp, Linda Stein Gold, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque PsoriasisAndrew Blauvelt, Lawrence J. Green, Mark G. Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed CombinationLinda Stein Gold, Leon H Kircik, David Pariser, et al.
Pediatric Nephrology (Berlin, Germany)|January 12, 2007
Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseasesKesha Rana, Stephen Tonna, Yan Yan Wang, et al.
The Medical Journal of Australia|December 9, 2019
Predictors of ManuScript Rejection sYndrome (MiSeRY): a cohort studyHui-Chen Han, Anoop Ninan Koshy, Tina Lin, et al.
Cardiovascular Ultrasound|February 18, 2014
Left ventricular torsional dynamics post exercise for LV diastolic function assessmentMuhammad Asrar ul Haq, Vivek Mutha, Tina Lin, et al.
Pageof 12

Showing results (41-50 of 117) with videos related to

Sort By:
Pageof 12
The Journal of Clinical and Aesthetic Dermatology|December 28, 2018
Safety and Efficacy of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination Lotion in the Treatment of Moderate-to-severe Plaque Psoriasis: A Comparison with Halobetasol Propionate 0.05% CreamNeal D Bhatia, David M Pariser, Leon Kircik, et al.
Journal of Drugs in Dermatology : JDD|July 14, 2018
Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of TherapyDavid M Pariser, Lawrence J Green, Linda Stein Gold, et al.
Small (Weinheim an Der Bergstrasse, Germany)|June 27, 2017
Creation of Faceted Polyhedral Microgels from Compressed EmulsionsJing Fan, Shin-Hyun Kim, Zi Chen, et al.
The Journal of Dermatological Treatment|September 17, 2019
Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technologyEmil A Tanghetti, Linda Stein Gold, James Q Del Rosso, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque PsoriasisLeon H. Kircik, Kim A. Papp, Linda Stein Gold, et al.
Journal of Drugs in Dermatology : JDD|March 26, 2019
Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque PsoriasisAndrew Blauvelt, Lawrence J. Green, Mark G. Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|August 21, 2018
Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed CombinationLinda Stein Gold, Leon H Kircik, David Pariser, et al.
Pediatric Nephrology (Berlin, Germany)|January 12, 2007
Nine novel COL4A3 and COL4A4 mutations and polymorphisms identified in inherited membrane diseasesKesha Rana, Stephen Tonna, Yan Yan Wang, et al.
The Medical Journal of Australia|December 9, 2019
Predictors of ManuScript Rejection sYndrome (MiSeRY): a cohort studyHui-Chen Han, Anoop Ninan Koshy, Tina Lin, et al.
Cardiovascular Ultrasound|February 18, 2014
Left ventricular torsional dynamics post exercise for LV diastolic function assessmentMuhammad Asrar ul Haq, Vivek Mutha, Tina Lin, et al.
Pageof 12